For instance, TKIs targeting sensitive mutations in epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and osimertinib, prolong progression-free survival (PFS) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC), with acceptable adverse events during treatment [2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.